secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001420720-25-000033
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

iBio Reports Preclinical Data for IBIO-610 Showing Extended Half-Life in Obese Non-Human Primates
--------------------------------------------------------------------------------

- IBIO-610 half-life in obese NHP measured at 33.2 days.
- Predicted human half-life up to 100 days, enabling twice-yearly dosing.
- Data to be presented at ObesityWeek 2025, Nov 4-7 in Atlanta by Cory Schwartz, Ph.D.
- IBIO-610 is a potential first-in-class Activin E antibody for fat-selective weight loss.
- Previously showed GLP-1-synergistic weight loss and prevention of weight regain in mouse models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000033/0001420720-25-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000033/ibio-20251030x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-25-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer